These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35514019)

  • 1. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
    Enomoto M; Kaji K; Nishimura N; Fujimoto Y; Murata K; Takeda S; Tsuji Y; Fujinaga Y; Takaya H; Kawaratani H; Namisaki T; Akahane T; Yoshiji H
    Dig Liver Dis; 2022 Oct; 54(10):1392-1402. PubMed ID: 35514019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
    Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity.
    Fujimoto Y; Kaji K; Nishimura N; Enomoto M; Murata K; Takeda S; Takaya H; Kawaratani H; Moriya K; Namisaki T; Akahane T; Yoshiji H
    World J Gastroenterol; 2021 Dec; 27(48):8323-8342. PubMed ID: 35068872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
    Nakanishi K; Kaji K; Kitade M; Kubo T; Furukawa M; Saikawa S; Shimozato N; Sato S; Seki K; Kawaratani H; Moriya K; Namisaki T; Yoshiji H
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
    Douhara A; Moriya K; Yoshiji H; Noguchi R; Namisaki T; Kitade M; Kaji K; Aihara Y; Nishimura N; Takeda K; Okura Y; Kawaratani H; Fukui H
    Mol Med Rep; 2015 Mar; 11(3):1693-700. PubMed ID: 25421042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway.
    Lv S; Zhang Z; Su X; Li W; Wang X; Pan B; Li H; Zhang H; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():1106875. PubMed ID: 36743916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
    J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alleviation of cholestatic liver injury and intestinal permeability by lubiprostone treatment in bile duct ligated rats: role of intestinal FXR and tight junction proteins claudin-1, claudin-2, and occludin.
    Safari F; Sharifi M; Talebi A; Mehranfard N; Ghasemi M
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):2009-2022. PubMed ID: 36897372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human.
    Zong Y; Zhu S; Zhang S; Zheng G; Wiley JW; Hong S
    Neurogastroenterol Motil; 2019 Feb; 31(2):e13477. PubMed ID: 30284340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
    Sawada Y; Kawaratani H; Kubo T; Fujinaga Y; Furukawa M; Saikawa S; Sato S; Seki K; Takaya H; Okura Y; Kaji K; Shimozato N; Mashitani T; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yamao J; Yoshiji H
    Hepatol Res; 2019 Mar; 49(3):284-295. PubMed ID: 30365236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway.
    Leng J; Huang F; Hai Y; Tian H; Liu W; Fang Y; Hu Y; Peng J
    Phytomedicine; 2020 Jan; 66():153135. PubMed ID: 31790895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.
    Murata K; Kaji K; Nishimura N; Enomoto M; Fujimoto Y; Takeda S; Tsuji Y; Fujinaga Y; Takaya H; Kawaratani H; Namisaki T; Akahane T; Yoshiji H
    Int J Mol Med; 2022 Aug; 50(2):. PubMed ID: 35686541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
    Bae CR; Zhang H; Kwon YG
    PLoS One; 2020; 15(12):e0243497. PubMed ID: 33275637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic calcitriol supplementation improves the inflammatory profiles of circulating monocytes and the associated intestinal/adipose tissue alteration in a diet-induced steatohepatitis rat model.
    Su YB; Li TH; Huang CC; Tsai HC; Huang SF; Hsieh YC; Yang YY; Huang YH; Hou MC; Lin HC
    PLoS One; 2018; 13(4):e0194867. PubMed ID: 29684027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats.
    Jegatheesan P; Beutheu S; Freese K; Waligora-Dupriet AJ; Nubret E; Butel MJ; Bergheim I; De Bandt JP
    Br J Nutr; 2016 Jul; 116(2):191-203. PubMed ID: 27197843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient L-amino acid-defined diet-induced murine model.
    Yang YM; Wang Z; Matsuda M; Seki E
    Arch Pharm Res; 2021 Feb; 44(2):230-240. PubMed ID: 33486695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A trans fatty acid substitute enhanced development of liver proliferative lesions induced in mice by feeding a choline-deficient, methionine-lowered, L-amino acid-defined, high-fat diet.
    Suzuki-Kemuriyama N; Abe A; Uno K; Ogawa S; Watanabe A; Sano R; Yuki M; Miyajima K; Nakae D
    Lipids Health Dis; 2020 Dec; 19(1):251. PubMed ID: 33317575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.